PBAC's latest decision on Quetiapine: Recommended with restriction (2018). Considered for Maintenance therapy for treatment of acute mania and bipolar I disorder, and in the treatment of schizophrenia.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
7
first 2010
Submissions
7
2010 → 2018
Eligible population
Patients with schizophrenia, acute mania associated with bipolar I disorder, or bipolar I disorder requiring maintenance therapy at doses not adequately provided by other strengths of quetiapine (e.g. 37.5 mg or 52.5 mg).
Therapy area
Mental health
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled — this is a minor administrative submission concerning repeats for an existing listing, not a new clinical or economic evaluation.
ICER (historical)
$45k/QALY–$75k/QALY across 2 submissions (2010–2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2010: Recommended with restriction · Authority Required (Streamlined)
Nov 2010: Not recommended · Authority Required (Streamlined) — ICER $45k/QALY
Nov 2010: Not recommended
2011: Not recommended · Authority Required (STREAMLINED) — ICER $75k/QALY
Jul 2013: Not recommended · Authority Required
Aug 2013: Recommended with restriction · Authority Required
Jul 2018: Recommended with restriction · Authority Required